Health chiefs confirm weight loss drugs can trigger potentially fatal organ-destroying side effect

Health authorities in the UK have recently updated guidance regarding a potential, though rare, risk associated with a class of medications increasingly used for both type 2 diabetes and weight management. The Medicines and Healthcare products Regulatory Agency (MHRA) has revised product information for healthcare professionals and patients concerning GLP-1 drugs, including Ozempic, Wegovy, and Mounjaro.

Understanding the Updated Guidance

The updated guidance centers around a “small risk of severe acute pancreatitis” for individuals taking these medications. Acute pancreatitis involves inflammation of the pancreas. While most cases resolve on their own, more serious complications – including stomach pain, nausea, and vomiting – can occur. In the most severe instances, pancreatitis can lead to multiple organ failure and, tragically, can be fatal.

Did You Know? Between 2007 and October 2025, the MHRA received 1,296 reports of pancreatitis potentially linked to GLP-1 receptor agonists.

How Common is the Risk?

According to the NHS, approximately one in five severe cases of acute pancreatitis results in life-threatening complications. However, Dr. Alison Cave, chief safety officer at the MHRA, emphasized that the risk of developing these severe side effects remains “very small.” The MHRA continues to monitor the safety and effectiveness of all licensed medicines.

These drugs – Ozempic and Wegovy, and Mounjaro – are prescribed for Type-2 diabetes, with Wegovy and Mounjaro also available through the NHS for weight loss. Estimates suggest that around 1.6 million adults in England, Wales, and Scotland used GLP-1 drugs for weight loss between 2024 and 2025, with an additional 3.3 million expressing interest in doing so in 2026.

Expert Insight: The MHRA’s proactive update to prescribing information highlights the importance of ongoing pharmacovigilance – the continuous monitoring of drug safety – even after a medication has been approved for use. This demonstrates a commitment to transparency and patient safety as these drugs become more widely adopted.

What Do Manufacturers Say?

Novo Nordisk, the manufacturer of Ozempic and Wegovy, affirmed their commitment to patient safety and stated that the benefit-risk profile of their GLP-1 medicines remains positive. Eli Lilly, the manufacturer of Mounjaro, also emphasized patient safety and noted that their product information leaflet already warns of the potential for pancreatitis. Both companies are working with the MHRA to ensure healthcare providers have access to the latest safety information.

What Might Happen Next?

It is possible that healthcare professionals may increase their vigilance for symptoms of pancreatitis in patients taking these medications. The MHRA could continue to monitor reports of adverse events and potentially issue further guidance if new data emerges. Patients and healthcare providers may engage in more detailed discussions about the potential risks and benefits of GLP-1 drugs before initiating treatment. Further research into the link between these medications and pancreatitis is also a possibility.

Frequently Asked Questions

What are the symptoms of acute pancreatitis?

According to the NHS, symptoms of acute pancreatitis include severe, persistent stomach pain that may radiate to the back, and may be accompanied by nausea and vomiting.

Which drugs are affected by this new guidance?

The updated guidance applies to GLP-1 drugs such as Ozempic, Wegovy, and Mounjaro.

What should I do if I experience these symptoms while taking a GLP-1 drug?

The MHRA advises individuals experiencing symptoms such as severe, persistent stomach pain, nausea, and vomiting while taking GLP-1s to speak to a healthcare professional and report it via their Yellow Card scheme.

Given this new information, how will you discuss potential risks and benefits with your healthcare provider when considering weight loss or diabetes management options?